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Background: VIBATIV is a once-daily, injectable lipoglycopeptide antibiotic approved in the U.S. for the
treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused byKey words:
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susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable. In addition,
VIBATIV is approved in the U.S. for the treatment of adult patients with complicated skin & skin structure
infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including Staphylococcus
aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains.
Objective: To evaluate the chemical stability of telavancin (Vibativ; Theravance Biopharma US, Inc,
Northbrook, Illinois), a lipoglycopeptide antibiotic with activity against methicillin-resistant Staph-
ylococcus aureus, in 2 types of elastomeric pumps, the Intermate Infusion System (Baxter International
Inc) and the Homepump Eclipse (I-Flow Corporation).
Methods: Different sizes of the Baxter (Ontario, Canada) (105 mL and 275 mL) and I-Flow (Stoughton,
Massachusetts) (100 mL and 250 mL) pumps were compared with glass controls. The telavancin drug
product was reconstituted and diluted to concentrations of 0.6 mg/mL and 8.0 mg/mL using either 0.9%
saline, 5% dextrose in water, or sterilized water for injection (0.6 mg/mL telavancin) or saline (8.0 mg/mL
telavancin) followed by Ringer’s Lactate solution. Pumps were ﬁlled and stored at 21C to 81C, protected
from light. Aliquots from both pump types and for all telavancin reconstitution/dilution schemes and
concentrations were taken over a period of 8 days and analyzed for appearance, pH, telavancin
concentration and purity, and degradation products.
Results: The pH of all pump solutions remained consistent throughout the 8-day analysis period, within
a range of 4.6 to 5.7 for the 0.6 mg/mL and 4.4 to 4.9 for the 8.0 mg/mL telavancin solutions. There was no
signiﬁcant change in the chromatographic purity for any of the pump solutions examined. All decreases
in telavancin concentration were r2.7%. Comparison of each test sample solution to the corresponding
glass control indicated no loss of active drug due to absorption by the elastomeric material of the pumps.
The greatest increase in the amount of total degradants observed over the 8-day period was 0.7 w/w%.
Conclusions: The results of this study indicate that telavancin remains chemically stable when diluted in
the Intermate Infusion System and the Homepump Eclipse elastomeric pumps and stored at 21C to 81C
for up to 8 days protected from light at the concentration range and dilution schemes evaluated.
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Study Registry Identiﬁcation Number:Introduction
Telavancin (Vibativ; Theravance Biopharma Antibiotics, Inc,
South San Francisco, California) is a lipoglycopeptide antibioticInc. This is an open access article u
eeting and Exposition of the
sts, October 23–27, 2011;
harmD, Medical Information
outh San Francisco, CA 94080.
r).approved in the United States and Canada. This novel anti-infective
agent treats patients with complicated skin and skin structure
infections due to susceptible gram-positive pathogens. Additionally,
in the United States and Europe, telavancin is approved for treating
hospital-acquired bacterial pneumonia, including ventilator-
associated bacterial pneumonia due to susceptible isolates of
Staphylococcus aureus (methicillin-resistant S aureus strains only
in Europe), when alternative medicines are unsuitable. The rec-
ommended dosing of both indications for telavancin is 10 mg/kg
administered over a 60-minute period in patients aged 18 years
and older by intravenous infusion once every 24 hours for 7 to
21 days.1nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table I
Elastomeric pump part information.
Pump Size (mL) Flow rate (mL/h)
Baxter Intermate* Infusion System 275 100†
105 100
I-Flow Homepump Eclipse‡ 250 175†
100 100
n Ontario, Canada
† Delivery time is 460 minutes
‡ Stoughton, Massachusetts
P. Sand et al. / Current Therapeutic Research 77 (2015) 99–104100Studies have shown that the reconstituted solution in the vial
should be used within 7 days under refrigeration at 21C to 81C
(361F–461F). The ﬁnal solution in the infusion bag should also be
used within 7 days when stored under refrigeration at 21C to 81C
(361F–461F). However, the total time in the vial plus the time in the
infusion bag should not exceed 7 days under refrigeration at 21C to
81C (361F–461F). The ﬁnal solution in the infusion bag can also be
stored at 301C to 101C (221F to 141F) for up to 32 days.1
The 24-hour dosing interval is also compatible with outpatient
parenteral antimicrobial therapy (OPAT).2 Disposable infusion
pumps, known as elastomeric devices, are attractive providers Of
OPAT due to their portability, simplicity, and ease of disposal;
patients have preferred elastomeric devices over electronically
controlled pumps due to the aforementioned reasons.3,4 The
Intermate Infusion System (Baxter International Inc, Ontario,
Canada) and the Homepump Eclipse (I-Flow Corporation,
Stoughton, Massachusetts) are 2 commonly used elastomeric
infusion pumps. Stability is an essential consideration when using
elastomeric pumps. Two other antibiotics, doripenem and mero-
penem, have been shown to be stable in elastomeric containers for
at least 7 days when stored between 4ºC and 5ºC (391F–411F).5,6Objective
This study investigated the chemical stability of telavancin
when reconstituted and stored over an extended period in
Intermate Infusion System and Homepump Eclipse pumps. Micro-
biologic testing was not carried out during this study.Methods
Telavancin for injection vials (750 mg/vial) were reconstituted
and pooled in a glass volumetric ﬂask before being diluted to
concentrations of 0.6 mg/mL and 8.0 mg/mL using 1 of 3 reconstitu-
tion/dilution solutions: normal saline (0.9%) as reconstitution sol-
ution and diluent, dextrose in water (5%) as reconstitution solution
and diluent, or sterile water for injection (0.6 mg/mL telavancin) or
saline (8.0 mg/mL telavancin) followed by Ringer’s Lactate solution as
diluent. The reconstituted telavancin solution and the diluent were
not preﬁltered and were added in different volumetric sizes of either
the Intermate Infusion System (105 mL and 275 mL) or Homepump
Eclipse (100 mL and 250 mL) pumps (Table I).Table II
Preparation of test articles and glass control solutions from vials of telavancin for inject
Test articles and solutions Telavancin test solution
Final concentration in pump, mg/mL 0.6
Total solution volume in pump, mL 100.0 250
Volume of pooled reconstituted vial solution, mL 4.0 10
Diluent volume, mL 96.0 240Pumps were ﬁlled by adding the appropriate amount of the
pooled reconstituted solution and diluent using sterile syringes of
various sizes (1–60 mL) ﬁtted with 18-gauge needles. The glass
control solutions were dilutions of the pooled telavancin stock
solution prepared to concentrations of 0.6 mg/mL and 8.0 mg/mL
in glass volumetric ﬂasks (Table II). Once the reconstituted
telavancin solutions were mixed with their respective diluents,
the ﬁlled pumps and glass controls were stored at 21C to 81C and
protected from light to mimic expected storage and handling.
Samples from both pump types, for all telavancin reconstitu-
tion/dilution schemes and concentrations, were removed via the
pump tubing at the initial (T0,15–30 minutes after preparation), 24-
, 48-, 72-, 96-, 120-, 144-, 168-, and 192-hour (T192) time points and
were immediately compared with glass controls assessed at T0. At
each sample pull time point, the pumps were removed to ambient
conditions under low-actinic (yellow) lighting brieﬂy to remove
the testing aliquot, then returned to darkened storage. The pH of
each sample was measured only at T0 and T192. The appearance of
each sample was examined at all sample pull time points.
Sample aliquots were diluted to 0.2 mg/L with the appropriate
diluent and assayed for telavancin concentration, purity, and
degradation products by reverse phase high-performance liquid
chromatography (HPLC). The HPLC method was validated in
accordance with the International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceuticals for
Human Use guideline Q2(R1). The HPLC system (Agilent 1100;
Agilent Technologies, Inc, Santa Clara, California) was equipped
with a binary pump, a single wavelength ultraviolet detector, a
refrigerated autosampler, a C18 analytical column (Waters SunFire;
Waters Corporation, Milford, Massachusetts), and was controlled
using Empower acquisition software (Waters Corporation, Milford,
MA). Mobile Phase A consisted of 2% acetonitrile: 98% water: and
0.05% formic acid. Mobile Phase B consisted of 60% acetonitrile:
40% water: and: 0.05% formic acid. The HPLC gradient was set as
follows for Mobile Phase A: 0 minutes at 90%: 20 minutes at 85%,
30 minutes at 80%, 50 minutes at 60%, and 50.5 minutes at 0%
followed by a washout and equilibration period. The ﬂow rate was
1.0 mL/min and the injection volume was 80 μL. Quantitation was
performed by integration of the peaks at a detection wavelength of
230 nm.Results
The visual appearance of all pump solutions remained clear and
essentially free from visible particulate matter at all time points
examined. There were no signiﬁcant changes in pH in any of the
pump solutions from T0 to T192, with maximum ranges in pH
throughout the analysis period of 4.6–5.7 and 4.4–4.9 for the
0.6 mg/mL and 8.0 mg/mL telavancin solutions, respectively
(Table III).
Comparison of T0 to T192 concentration assay data for each
pump solution demonstrated that there were no signiﬁcant
changes in telavancin concentrations (Table III). Although the
assays were not done in triplicate, the stability results in other
storage containers (ie, frozen nonpolyvinyl chloride [PVC] bags andion (750 mg/vial).
Glass controls
8.0 0.6 8.0
.0 100.0 250.0 100.0 100.0
.0 53.3 133.3 4.0 53.3
.0 46.7 116.7 96.0 46.7
Table III
Elastomeric pump stability of telavancin in the Intermate Infusion System (Baxter, Ontario, Canada) and Homepump Eclipse (I–Flow Corp, Stoughton, Massachusetts) pumps.
Fill
volume,
mL*
Target
concen-
tration,
mg/mL
Reconstitution/
dilution
solutions
Assay,
mg/mL
Assay
change
HPLC
purity, %
pH Degradant
A, w/w%
Degradant
B, w/w%
Total
degradants,
w/w%
Recovery vs
glass
control, %
T0 T192 Overall,
mg/mL
Percent-
age, %†
T0 T192 T0 T192 T0 T192 T0 T192 T0 T192 T0 T192 Change
Intermate Infusion System
100 0.6 NaCl/NaCl 0.541 0.542 0.001 0.2 92.3 91.7 5.2 5.0 0.16 0.15 1.50 1.85 1.7 2.0 96.3 96.4 0.2
250 0.6 NaCl/NaCl 0.554 0.555 0.001 0.2 92.4 91.6 5.3 5.0 0.16 0.14 1.50 1.87 1.7 2.0 98.7 98.8 0.1
100 0.6 D5W/D5W 0.617 0.609 –0.008 –1.3 91.8 90.6 4.8 4.6 0.16 0.12 1.67 2.33 1.8 2.5 100.4 99.1 1.3
250 0.6 D5W/D5W 0.618 0.612 –0.006 –1.0 91.8 90.8 4.7 4.7 0.13 0.11 1.52 2.14 1.6 2.3 100.8 99.9 1.0
100 0.6 SWFI/LR 0.603 0.591 –0.012 –2.0 91.9 90.9 5.6 5.6 0.14 0.12 1.60 1.95 1.7 2.1 99.5 97.6 1.9
250 0.6 SWFI/LR 0.605 0.589 –0.016 –2.7 91.9 91.0 5.7 5.5 0.15 0.12 1.58 1.97 1.7 2.1 99.8 97.2 2.7
100 8.0 NaCl/NaCl 8.040 8.050 0.010 0.1 91.5 91.7 4.8 4.8 0.14 0.18 1.38 1.69 1.5 1.9 100.5 100.7 0.1
250 8.0 NaCl/NaCl 8.030 7.980 –0.050 –0.6 91.4 91.9 4.8 4.8 0.17 0.18 1.39 1.71 1.6 1.9 100.4 99.8 0.6
100 8.0 D5W/D5W 8.080 8.030 –0.050 –0.6 91.8 90.9 4.5 4.5 0.12 0.11 1.48 1.92 1.6 2.0 100.0 99.3 0.6
250 8.0 D5W/D5W 8.050 8.000 –0.050 –0.6 92.1 91.0 4.4 4.5 0.10 0.13 1.47 1.94 1.6 2.1 99.7 99.0 0.7
100 8.0 NaCl/LR 8.280 8.170 –0.110 –1.3 92.3 91.4 4.8 4.7 0.13 0.14 1.54 1.91 1.7 2.1 100.4 99.1 1.3
250 8.0 NaCl/LR 8.180 8.100 –0.080 –1.0 92.1 91.4 4.8 4.8 0.13 0.12 1.54 1.91 1.7 2.0 99.2 98.2 1.0
Homepump Eclipse
100 0.6 NaCl/NaCl 0.549 0.545 –0.004 –0.7 92.0 91.4 5.1 5.3 0.16 0.14 1.51 1.90 1.7 2.0 97.7 97.0 0.7
250 0.6 NaCl/NaCl 0.547 0.544 –0.003 –0.6 92.2 91.7 5.1 5.2 0.15 0.13 1.47 1.90 1.6 2.0 97.4 96.8 0.6
100 0.6 D5W/D5W 0.617 0.615 –0.002 –0.3 91.8 90.4 4.8 4.9 0.13 0.10 1.52 2.17 1.6 2.3 100.7 100.3 0.3
250 0.6 D5W/D5W 0.614 0.615 0.001 0.2 91.5 90.7 4.8 4.9 0.12 0.10 1.52 2.20 1.6 2.3 100.1 100.4 0.2
100 0.6 SWFI/LR 0.599 0.586 –0.013 –2.2 91.9 91.0 5.7 5.6 0.13 0.11 1.59 1.95 1.7 2.1 99.0 96.8 2.2
250 0.6 SWFI/LR 0.608 0.594 –0.014 –2.3 92.1 91.4 5.6 5.7 0.14 0.12 1.60 1.96 1.7 2.1 100.4 98.1 2.3
100 8.0 NaCl/NaCl 8.000 7.990 –0.010 –0.1 91.4 91.9 4.8 4.9 0.17 0.17 1.40 1.71 1.6 1.9 100.1 100.0 0.1
250 8.0 NaCl/NaCl 8.020 8.050 0.030 0.4 91.5 91.7 4.8 4.8 0.16 0.18 1.43 1.69 1.6 1.9 100.4 100.7 0.3
100 8.0 D5W/D5W 8.060 8.060 0.000 0.0 91.9 91.0 4.4 4.5 0.11 0.11 1.50 1.91 1.6 2.0 99.7 99.8 0.1
250 8.0 D5W/D5W 8.010 7.980 –0.030 –0.4 92.1 91.0 4.6 4.5 0.11 0.09 1.50 1.93 1.6 2.0 99.2 98.8 0.4
100 8.0 NaCl/LR 8.240 8.140 –0.100 –1.2 92.2 91.1 4.8 4.8 0.13 0.13 1.55 1.92 1.7 2.1 99.9 98.7 1.2
250 8.0 NaCl/LR 8.230 8.140 –0.090 –1.1 92.1 91.4 4.8 4.7 0.14 0.12 1.56 1.91 1.7 2.0 99.8 98.8 1.0
D5W ¼ 5% dextrose; HPLC ¼ high-performance liquid chromatography; LR ¼ Ringer’s Lactate; NaCl ¼ normal saline (0.9% sodium chloride); SWFI ¼ sterile water for injection.
n Fill volumes of 100 mL and 250 mL were used for the 105 mL and 275 mL pumps, respectively.
† Due to mathematical computation and rounding, the exact values may not be accurate.
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Figure 1. Chromatographic purity in the Intermate Infusion System pump (Baxter International Inc, Ontario, Canada). A ﬁll volume of 250 mL and a target concentration of
0.6 mg/mL were used, reconstituted in sterile water for injection, and diluted in Ringer’s Lactate solution.
P. Sand et al. / Current Therapeutic Research 77 (2015) 99–104102frozen PVC bags) are similar to those in elastomeric devices.7
Based on the storage environment, multiple concentrations, recon-
stitution solutions, and diluents, the greatest change in assay
results over the 192-hour study period were noted in 100 mL of
the 8 mg/mL concentration of telavancin with normal saline as the
reconstituting solution and Ringer’s Lactate being the diluent; the
changes observed were 0.11 mg/mL and 0.10 mg/mL in the
Intermate Infusion System and Homepump Eclipse, respectively.
Comparison of each test sample to a corresponding glass
control indicated no loss of active drug due to absorption by the
elastomeric material of either type of pump (Table III). The initial
mean overall recovery assays in the Intermate Infusion System in
sterile water/lactated Ringer’s solution at T0 and T192 were 0.605
mg/mL and 0.589 mg/mL, respectively, with an overall 2.7%
decrease in telavancin concentration when compared with glass
control. The greatest decrease for both pump types was seen in the
0.6 mg/mL sterile water/Ringer’s Lactate solution, 250 mL pump
size conﬁguration (Table III). There was no corresponding change
in the amount of Degradant B in these solutions, because Degra-
dant B was regarded as the primary degradation product of
telavancin.7
There was no signiﬁcant change in chromatographic purity for
any of the pump solutions examined during this study (Table III),as depicted in representative chromatograms for each pump at the
target concentration of 0.6 mg/mL and pump size conﬁguration of
250 mL (Figures 1 and 2). Additionally, the largest increase in total
degradants observed was 0.7 w/w% over the 8-day period, seen
in both sizes of both pumps at the 0.6 mg/mL telavancin concen-
tration (Table III). This amount of increase was consistent with
telavancin stability testing and the total degradant values at T192 as
well as the ﬁrst appearance of degradants A and B at approx-
imately 8.5 and 14.7 minutes after elution (Figures 1 and 2) fall
within the acceptable range from previous studies.7Discussion
We have demonstrated that telavancin remains chemically
stable when reconstituted, diluted, and stored (protected from
light at 21C–81C) for up to 8 days in the Intermate Infusion System
and the Homepump Eclipse elastomeric pumps, for the reconsti-
tution/dilution schemes evaluated in this study. Further, HPLC
comparison of telavancin concentrations in the pump solutions
with glass controls indicate that active drug is not absorbed by the
container components of either pump assessed during this study
to any appreciable extent. There was no apparent inﬂuence on
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Figure 2. Chromatographic purity in the Homepump Eclipse pump (I-Flow Corp, Stoughton, Massachusetts). A ﬁll volume of 250 mL and a target concentration of 0.6 mg/mL
were used, reconstituted in sterile water for injection, and diluted in Ringer’s Lactate solution.
P. Sand et al. / Current Therapeutic Research 77 (2015) 99–104 103chromatographic purity due to contact with the pump surfaces,
further evidenced by negligible increases in the amount of
degradants.
Use of antimicrobial agents compatible with OPAT—from a
stability, dosing interval, and safety perspective—along with the
identiﬁcation of patients appropriate for OPAT, is key to ensuring
favorable outcomes.2,8 In addition to being often preferable for
patients in terms of comfort and convenience, the hospital cost
savings from using OPAT can be signiﬁcant due to shorter hospital
stays and lower incidence of costly nosocomial infections.8,9 Addi-
tional research into the safety of telavancin in the outpatient
setting, together with evidence to aid identiﬁcation of the patients
most appropriate for telavancin OPAT, is needed.
There are limitations to this study. Different models of elasto-
meric pumps are available and, as such, the ﬁndings of this study
could not be extrapolated to other pumps that differ from
the Intermate Infusion System and Homepump Eclipse with
alternative designs, composed of different elastomeric materials
(eg, polyurethane or PVC), or the use of other diluents; conse-
quently, telavancin stability or degradation in other elastomeric
devices could not be veriﬁed at present and additional investiga-
tion is warranted.Conclusions
The results of this study indicate that reconstituted telavancin
diluted in the Baxter Intermate Infusion System and I-Flow Home-
pump Eclipse elastomeric pumps retain purity and chemical stability
for up to 8 days when stored between 2ºC and 8ºC and protected
from light. Reconstituted telavancin diluted in elastomeric pumps
may be a viable drug delivery option for patients requiring OPAT
with telavancin for the approved indications; additional evidence
regarding the appropriate use of telavancin in this setting is required.Acknowledgments
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